http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전기 집진기의 진동 탈진을 위한 전자기 진동 가진기의 집중매개변수 모델링 및 해석
김제훈(Je-Hoon Kim),이정훈(Jung-Hun Lee),김진호(Jin-Ho Kim),정상현(Sang-Hyun Jeong),한방우(Bang-Woo Han) 한국자기학회 2011 韓國磁氣學會誌 Vol.21 No.2
The miniaturization of electrostatic precipitator is becoming a key element to the success of the efficient electrostatic precipitator due to the limited space allowed to install electrostatic precipitator in subway tunnel. Nowadays, a research on electrostatic precipitator in urban railroad equipment technology is under an active study. Finite element method has been used one of the most popular techniques, but it consumes a lot of time especially in computation iterations. Accordingly, the lumped parameter analysis can be an alternative tool to FEM because of its computation iteration capability with fair accuracy. In this paper, lumped parameter model and the simulation results are presented. In addition, the result of lumped parameter analysis is compared with those obtained from finite element analysis for verification.
이트라코나졸(itraconazole)액의 첨가물에 의해 발생한 지연형 두드러기 및 혈관부종 1예
김수영 ( Soo Young Kim ),최길순 ( Gil Soon Choi ),김희규 ( Hee Kyoo Kim ),김제훈 ( Je Hun Kim ),김철수 ( Cheol Su Kim ),양정욱 ( Joung Wook Yang ),유가인 ( Ga In You ),이진영 ( Jin Young Lee ) 대한천식알레르기학회(구 대한알레르기학회) 2014 Allergy Asthma & Respiratory Disease Vol.2 No.2
Itraconazole, new triazole agent with a broader antifungal spectrum than fluconazole, has been prescribed widely in the treatment and prophylaxis for fungal infection. Itaconazole has been reported to have gastrointestinal disturbance (4%) and headache (1%) as its most common side-effects. However, allergic reactions caused by this drug are rare. A 53 year-old woman with myelodysplastic syndrome received prophylactic antibiotic therapy including itraconazole solution before chemotherapy. She complained of hive on the face with angioedema at 6 hours after taking them. The symptoms were more aggravated on the next day and reversed by stopping itraconazole solution and injection of antihistamine and steroids. Skin prick tests with itraconazole solution, itraconazole tablet, and ketoconazole showed all the negative responses. The oral challenge test with itraconazole solution was performed and resulted in urticaria and angioedema 6 hours later. Next, the oral challenge test with intraconazole tablet was performed and showed negative response. The patient was finally diagnosed as adverse reaction by additives contained intraconazole solution. We report, a case of delayed onset urticaria and angioedema caused by components of itraconazole solution. (Allergy Asthma Respir Dis 2014;2:138-141)
진행성 대장암 환자에서 FOLFOX4 복합화학약물 치료의 실패 후 2차 요법으로 FOLFIRI 복합화학약물 치료의 효과와 안전성
김재현 ( Jae Hyun Kim ),박선자 ( Seun Ja Park ),박무인 ( Moo In Park ),문원 ( Won Moon ),김성은 ( Sung Eun Kim ),구기환 ( Ki Hwan Ku ),송성은 ( Sung Eun Song ),김제훈 ( Je Hun Kim ) 대한소화기학회 2014 대한소화기학회지 Vol.63 No.1
Background/Aims: The incidence of colorectal cancer has been increasing every year in Korea. Irinotecan- or oxaliplatin-based regimens including biologic agents are known to be effective in patients with advanced colorectal cancer. But in practice, FOLFOX (combination of oxaliplatin, 5-fluorouracil, and leucovorin) or FOLFIRI (combination of irinotecan, 5-fluorouracil, and leucovorin) regimens without biologic agents are more commonly used in Korea due to of the high costs of biologic agents. The aim of this study was to evaluate the efficacy and toxicity of FOLFIRI following FOLFOX4 in patients with advanced colorectal cancer. Methods: A total of 54 patients with advanced colorectal cancer who were treated between May 2005 and May 2013 with FOLFOX4 as first-line chemotherapy and with FOLFIRI as second-line chemotherapy at Kosin University Gospel Hospital (Busan, Korea) were reviewed retrospectively. Results: A total of 54 patients received second-line FOLFIRI chemotherapy. Five patients (9.3%) had a partial response, 29 patients (53.7%) had a stable disease. The median overall survival was 8.90 months and the median time to progression was 4.33 months. Toxicities were tolerable. Conclusions: In a Korean population, FOLFIRI as second-line chemotherapy is effective and well tolerated in patients with advanced colorectal cancer after failure of FOLFOX4. Although the efficacy of FOLFIRI in this study was lower than that of second-line FOLFIRI with biologic agents, these results can help in the formulation of a treatment strategy for financially troubled patients. (Korean J Gastroenterol 2014;63:18-24)